Hansom Pharmaceuticals (03692.HK) released its interim financial results, with a net profit attributable to shareholders of 3.135 billion yuan, an increase of 15.02% year-on-year.

Wisdom Financial News APP, Hanson Pharmaceuticals (03692.HK) released its interim performance for the six months ending June 30, 2025. The group achieved revenue of 7.434 billion yuan (same unit below), an increase of 14.27% year-on-year; the profit attributable to the owners of the parent company was 3.135 billion yuan, an increase of 15.02% year-on-year; earnings per share were 0.53 yuan, and it is planned to distribute an interim dividend of 23.16 Hong Kong cents per share.